PMID- 28098895
OWN - NLM
STAT- MEDLINE
DCOM- 20170425
LR  - 20170425
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 37
IP  - 3
DP  - 2017 Mar
TI  - MicroRNA-133b is regulated by TAp63 while no gene mutation is present in 
      colorectal cancer.
PG  - 1646-1652
LID - 10.3892/or.2017.5371 [doi]
AB  - Downregulation of miR-133b has been reported in multiple types of malignancies 
      including colorectal cancer (CRC). We previously confirmed that TAp63 actively 
      translates microRNA-133b (miR-133b) transcripts. While the presence of miRNA 
      mutations have frequently been described in CRC, most CRCs do not show any 
      variation in the miR‑133b coding sequence. Therefore, it is important to 
      elucidate the relationship between TAp63 and miR-133b, and identify other 
      mediators of miR-133b downregulation in CRC. The expression of TAp63 was detected 
      by RT-qPCR, western blotting, immunohistochemistry (IHC) and densitometric 
      analysis using Image-Pro Plus 6.0 software in 38 CRC and corresponding 
      non-cancerous tissues (NCTs). The expression of mature miR‑133b was determined by 
      RT-qPCR, in situ hybridization (ISH) and densitometric analysis using Image-Pro 
      Plus 6.0 software. The DNA from 38 CRC tissues and NCTs were screened for 
      miR-133b mutations through sequence analysis. Compared with the NCTs, TAp63 mRNA 
      expression was significantly lower in 21 (55.27%) tumor tissues. Compared with 
      the NCTs, the miR‑133b expression level was significantly lower in 31 (81.58%) 
      tumor tissues. The expression of miR‑133b was found to be positively correlated 
      with TAp63. Loss of TAp63 and miR-133b was associated with an increased 
      likelihood of metastatic events. The area under the ROC curve (AUC) of TAp63 for 
      CRC was 0.623 [95% confidence interval (CI), 0.497-0.748; P=0.046], with 73.7% 
      sensitivity and 50% specificity, respectively. The AUC of miR-133b for CRC was 
      0.857 (95% CI, 0.774‑0.940; P<0.0001), with 78.9% sensitivity and 81.6% 
      specificity, respectively. The combined AUC of TAp63 and miR-133b for CRC was 
      0.881 (95% CI, 0.805-0.956; P<0.0001), with 89.5% sensitivity and 71.1% 
      specificity, respectively. Point mutations within the seed region of miR-133b 
      were found in 1 patient, but the point mutation did not impact the secondary 
      structure of the pre-miR-133b. Therefore, downregulation of TAp63 may be one 
      reason for the dysregulation of miR‑133b in CRC. The expression analysis of TAp63 
      and miR-133b revealed that they may be used as valuable prognostic biomarkers for 
      CRC.
FAU - Chen, Yifei
AU  - Chen Y
AD  - Department of Gastrointestinal Surgery, The Third XiangYa Hospital of Central 
      South University, Changsha, Hunan 410013, P.R. China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Department of Oncological Surgery, Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, Jiangsu 221000, P.R. China.
FAU - He, Jianhuai
AU  - He J
AD  - Department of Breast, Thyroid and Vascular Surgery, Chenzhou No. 1 People's 
      Hospital, Chenzhou, Hunan 423000, P.R. China.
FAU - Fu, Ying
AU  - Fu Y
AD  - Department of Gastrointestinal Surgery, The Third XiangYa Hospital of Central 
      South University, Changsha, Hunan 410013, P.R. China.
FAU - Lin, Changwei
AU  - Lin C
AD  - Department of Gastrointestinal Surgery, The Third XiangYa Hospital of Central 
      South University, Changsha, Hunan 410013, P.R. China.
FAU - Li, Xiaorong
AU  - Li X
AD  - Department of Gastrointestinal Surgery, The Third XiangYa Hospital of Central 
      South University, Changsha, Hunan 410013, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170116
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN133 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
RN  - 0 (TP63 protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Proteins)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Blotting, Western
MH  - Colorectal Neoplasms/genetics/metabolism/*pathology
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization
MH  - Lymphatic Metastasis
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - ROC Curve
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transcription Factors/genetics/*metabolism
MH  - Tumor Suppressor Proteins/genetics/*metabolism
EDAT- 2017/01/19 06:00
MHDA- 2017/04/26 06:00
CRDT- 2017/01/19 06:00
PHST- 2016/06/29 00:00 [received]
PHST- 2016/08/08 00:00 [accepted]
PHST- 2017/01/19 06:00 [pubmed]
PHST- 2017/04/26 06:00 [medline]
PHST- 2017/01/19 06:00 [entrez]
AID - 10.3892/or.2017.5371 [doi]
PST - ppublish
SO  - Oncol Rep. 2017 Mar;37(3):1646-1652. doi: 10.3892/or.2017.5371. Epub 2017 Jan 16.